Skip to main content
Erschienen in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie 9/2022

08.07.2022 | Reports of Original Investigations

Titrated versus conventional anticoagulation management for thrombin generation in cardiac surgery: a randomized controlled trial

verfasst von: Han Li, MSc, CPC, CPP, Justyna Bartoszko, MD, MSc, Cyril Serrick, MSc, CPC, MCCP, Vivek Rao, MD, PhD, Keyvan Karkouti, MD, MSc

Erschienen in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Optimal heparin titration during cardiopulmonary bypass (CPB) may reduce coagulation system activation and preserve hemostatic function post-CPB. Our objective was to assess if the Heparin Management System (HMS) Plus improves heparin titration, thereby leading to higher thrombin generation post-CPB compared with activated clotting time (ACT)-guided management.

Methods

We conducted a randomized controlled trial of 100 patients undergoing cardiac surgery with CPB at a single center. A total of 50 patients were randomized to conventional ACT-guided management, and 50 to the HMS Plus system. The primary outcome was change in thrombin generation post-CPB compared with baseline, as assessed by calibrated automated thrombography. Secondary outcomes included intraoperative blood loss, chest drain output up to 72 hr, and transfusions. In an exploratory analysis, we compared the quintile of patients with the highest average heparin concentration on CPB (≥ 4.0 mg⋅kg-1) with the rest of the cohort.

Results

A total of 100 patients were included in an intent-to-treat analysis. We observed no difference in post-CPB thrombin generation or secondary outcomes. However, patients in the HMS Plus group had higher average heparin concentrations while on CPB than patients in the conventional management group did (mean difference, -0.21; 95% confidence interval, -0.42 to -0.01). The quintile of patients with the highest average heparin concentration (4.0 mg⋅kg-1) had higher thrombin generation post-CPB than the rest of the cohort did.

Conclusions

The HMS Plus system did not show significant benefits in thrombin generation, bleeding outcomes, or transfusion in patients undergoing cardiac surgery with CPB. Higher average heparin concentrations on CPB were associated with higher post-CPB thrombin generation.

Study registration

www.​ClinicalTrials.​gov (NCT03347201); first submitted 12 October 2017.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fitzgerald J, McMonnies R, Sharkey A, Gross PL, Karkouti K. Thrombin generation and bleeding in cardiac surgery: a clinical narrative review. Can J Anesth 2020; 67: 746–53.CrossRef Fitzgerald J, McMonnies R, Sharkey A, Gross PL, Karkouti K. Thrombin generation and bleeding in cardiac surgery: a clinical narrative review. Can J Anesth 2020; 67: 746–53.CrossRef
2.
Zurück zum Zitat Bartoszko J, Karkouti K. Managing the coagulopathy associated with cardiopulmonary bypass. J Thromb Haemost 2021; 19: 617–32.CrossRef Bartoszko J, Karkouti K. Managing the coagulopathy associated with cardiopulmonary bypass. J Thromb Haemost 2021; 19: 617–32.CrossRef
3.
Zurück zum Zitat De Somer F, Van Belleghem Y, Caes F, et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2002; 123: 951–8.CrossRef De Somer F, Van Belleghem Y, Caes F, et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2002; 123: 951–8.CrossRef
4.
Zurück zum Zitat Höfer J, Fries D, Solomon C, Velik-Salchner C, Ausserer J. A snapshot of coagulopathy after cardiopulmonary bypass. Clin Appl Thromb Hemost 2016; 22: 505–11.CrossRef Höfer J, Fries D, Solomon C, Velik-Salchner C, Ausserer J. A snapshot of coagulopathy after cardiopulmonary bypass. Clin Appl Thromb Hemost 2016; 22: 505–11.CrossRef
5.
Zurück zum Zitat Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69: 685–9. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69: 685–9.
6.
Zurück zum Zitat Martindale SJ, Shayevitz JR, D'Errico C. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth 1996; 10: 458–63.CrossRef Martindale SJ, Shayevitz JR, D'Errico C. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth 1996; 10: 458–63.CrossRef
7.
Zurück zum Zitat Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 1999; 91: 1122–51.CrossRef Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 1999; 91: 1122–51.CrossRef
8.
Zurück zum Zitat Thompson TZ, Kunak RL, Savage NM, Agarwal S, Chazelle J, Singh G. Intraoperative monitoring of heparin: comparison of activated coagulation time and whole blood heparin measurements by different point-of-care devices with heparin concentration by laboratory-performed plasma anti-xa assay. Lab Med 2019; 50: 348–56.CrossRef Thompson TZ, Kunak RL, Savage NM, Agarwal S, Chazelle J, Singh G. Intraoperative monitoring of heparin: comparison of activated coagulation time and whole blood heparin measurements by different point-of-care devices with heparin concentration by laboratory-performed plasma anti-xa assay. Lab Med 2019; 50: 348–56.CrossRef
9.
Zurück zum Zitat Li H, Serrick C, Rao V, Yip PM. A comparative analysis of four activated clotting time measurement devices in cardiac surgery with cardiopulmonary bypass. Perfusion 2021; 36: 610–9.CrossRef Li H, Serrick C, Rao V, Yip PM. A comparative analysis of four activated clotting time measurement devices in cardiac surgery with cardiopulmonary bypass. Perfusion 2021; 36: 610–9.CrossRef
10.
Zurück zum Zitat Bloemen S, Hemker HC, Al Dieri R. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. Haematologica 2013; 98: 549–54.CrossRef Bloemen S, Hemker HC, Al Dieri R. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. Haematologica 2013; 98: 549–54.CrossRef
11.
Zurück zum Zitat Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1: validation of whole-blood heparin concentration and activated clotting time. Perfusion 2003; 18: 269–76. Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1: validation of whole-blood heparin concentration and activated clotting time. Perfusion 2003; 18: 269–76.
12.
Zurück zum Zitat Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108: 1076–82.CrossRef Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108: 1076–82.CrossRef
13.
Zurück zum Zitat Despotis GJ, Joist JH, Hogue CW Jr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110: 46–54. Despotis GJ, Joist JH, Hogue CW Jr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110: 46–54.
14.
Zurück zum Zitat Hofmann B, Bushnaq H, Kraus FB, et al. Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapy. Perfusion 2013; 28: 412–8.CrossRef Hofmann B, Bushnaq H, Kraus FB, et al. Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapy. Perfusion 2013; 28: 412–8.CrossRef
15.
Zurück zum Zitat Koster A, Fischer T, Praus M, et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002; 97: 837–41.CrossRef Koster A, Fischer T, Praus M, et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002; 97: 837–41.CrossRef
16.
Zurück zum Zitat Koster A, Huebler S, Merkle F, et al. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response. Anesth Analg 2004; 98: 285–90.CrossRef Koster A, Huebler S, Merkle F, et al. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response. Anesth Analg 2004; 98: 285–90.CrossRef
17.
Zurück zum Zitat Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4–15.CrossRef Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4–15.CrossRef
18.
Zurück zum Zitat Figueiredo Duarte RC, Ferreira CN, Alves Rios DR, Dos Reis HJ, das Graças Carvalho M. Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations. Rev Bras Hematol Hemoter 2017; 39: 259–65. Figueiredo Duarte RC, Ferreira CN, Alves Rios DR, Dos Reis HJ, das Graças Carvalho M. Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations. Rev Bras Hematol Hemoter 2017; 39: 259–65.
19.
Zurück zum Zitat Coakley M, Hall JE, Evans C, et al. Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding. J Thromb Haemost 2011; 9: 282–92.CrossRef Coakley M, Hall JE, Evans C, et al. Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding. J Thromb Haemost 2011; 9: 282–92.CrossRef
21.
Zurück zum Zitat Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother 2010; 1: 100–7.CrossRef Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother 2010; 1: 100–7.CrossRef
22.
Zurück zum Zitat Taam J, Yang QJ, Pang KS, et al. Current evidence and future directions of tranexamic acid use, efficacy, and dosing for major surgical procedures. J Cardiothorac Vasc Anesth 2020; 34: 782–90.CrossRef Taam J, Yang QJ, Pang KS, et al. Current evidence and future directions of tranexamic acid use, efficacy, and dosing for major surgical procedures. J Cardiothorac Vasc Anesth 2020; 34: 782–90.CrossRef
23.
Zurück zum Zitat Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists clinical practice improvement advisory for management of perioperative bleeding and hemostasis in cardiac surgery patients. J Cardiothorac Vasc Anesth 2019; 33: 2887–99.CrossRef Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists clinical practice improvement advisory for management of perioperative bleeding and hemostasis in cardiac surgery patients. J Cardiothorac Vasc Anesth 2019; 33: 2887–99.CrossRef
24.
Zurück zum Zitat Karkouti K, McCluskey SA, Callum J, et al. Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: a retrospective cohort study with interrupted time-series analysis. Anesthesiology 2015; 122: 560–70.CrossRef Karkouti K, McCluskey SA, Callum J, et al. Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: a retrospective cohort study with interrupted time-series analysis. Anesthesiology 2015; 122: 560–70.CrossRef
25.
Zurück zum Zitat Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists clinical practice improvement advisory for management of perioperative bleeding and hemostasis in cardiac surgery patients. Anesth Analg 2019; 129: 1209–21.CrossRef Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists clinical practice improvement advisory for management of perioperative bleeding and hemostasis in cardiac surgery patients. Anesth Analg 2019; 129: 1209–21.CrossRef
26.
Zurück zum Zitat Dargaud Y, Luddington R, Gray E, et al. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol 2007; 139: 303–9.CrossRef Dargaud Y, Luddington R, Gray E, et al. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol 2007; 139: 303–9.CrossRef
27.
Zurück zum Zitat Duarte RCF, Ferreira CN, Rios DRA, Reis HJD, Carvalho MDG. Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations. Rev Bras Hematol Hemoter 2017; 39: 259–65.CrossRef Duarte RCF, Ferreira CN, Rios DRA, Reis HJD, Carvalho MDG. Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations. Rev Bras Hematol Hemoter 2017; 39: 259–65.CrossRef
28.
Zurück zum Zitat Keularts IM, Zivelin A, Seligsohn U, Hemker HC, Béguin S. The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost 2001; 85: 1060–5.CrossRef Keularts IM, Zivelin A, Seligsohn U, Hemker HC, Béguin S. The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost 2001; 85: 1060–5.CrossRef
30.
Zurück zum Zitat Castoldi E, Rosing J. Thrombin generation tests. Thromb Res 2011; 127: S21–5.CrossRef Castoldi E, Rosing J. Thrombin generation tests. Thromb Res 2011; 127: S21–5.CrossRef
31.
Zurück zum Zitat Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 2016; 62: 699–707.CrossRef Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 2016; 62: 699–707.CrossRef
32.
Zurück zum Zitat Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27: 81–90.CrossRef Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27: 81–90.CrossRef
33.
Zurück zum Zitat Bosch YP, Al Dieri R, ten Cate H, et al. Measurement of thrombin generation intra-operatively and its association with bleeding tendency after cardiac surgery. Thromb Res 2014; 133: 488–94.CrossRef Bosch YP, Al Dieri R, ten Cate H, et al. Measurement of thrombin generation intra-operatively and its association with bleeding tendency after cardiac surgery. Thromb Res 2014; 133: 488–94.CrossRef
34.
Zurück zum Zitat Ofosu FA, Fernandez F, Gauthier D, Buchanan MR. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate. Semin Thromb Hemost 1985; 11: 133–7.CrossRef Ofosu FA, Fernandez F, Gauthier D, Buchanan MR. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate. Semin Thromb Hemost 1985; 11: 133–7.CrossRef
35.
Zurück zum Zitat Gravlee GP, Haddon WS, Rothberger HK, et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 1990; 99: 518–27. Gravlee GP, Haddon WS, Rothberger HK, et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 1990; 99: 518–27.
36.
Zurück zum Zitat Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1994; 58: 799–804.CrossRef Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1994; 58: 799–804.CrossRef
37.
Zurück zum Zitat Gravlee GP, Rogers AT, Dudas LM, et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992; 76: 393–401.CrossRef Gravlee GP, Rogers AT, Dudas LM, et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992; 76: 393–401.CrossRef
38.
Zurück zum Zitat Fernandez F, N'Guyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491–5.CrossRef Fernandez F, N'Guyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491–5.CrossRef
39.
Zurück zum Zitat Despotis GJ, Filos KS, Zoys TN, Hogue CW Jr, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996; 82: 13–21.PubMed Despotis GJ, Filos KS, Zoys TN, Hogue CW Jr, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996; 82: 13–21.PubMed
40.
Zurück zum Zitat Shigeta O, Kojima H, Hiramatsu Y, et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 118: 354–60.CrossRef Shigeta O, Kojima H, Hiramatsu Y, et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 118: 354–60.CrossRef
41.
Zurück zum Zitat Noui N, Zogheib E, Walczak K, et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion 2012; 27: 214–20.CrossRef Noui N, Zogheib E, Walczak K, et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion 2012; 27: 214–20.CrossRef
42.
Zurück zum Zitat Despotis GJ, Joist JH, Hogue CW Jr, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76: 902–8.CrossRef Despotis GJ, Joist JH, Hogue CW Jr, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76: 902–8.CrossRef
43.
Zurück zum Zitat Pappalardo F, Franco A, Crescenzi G, De Simone F, Torracca L, Zangrillo A. Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration. Perfusion 2006; 21: 285–90.CrossRef Pappalardo F, Franco A, Crescenzi G, De Simone F, Torracca L, Zangrillo A. Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration. Perfusion 2006; 21: 285–90.CrossRef
44.
Zurück zum Zitat Jeske W, Lormeau JC, Callas D, Iqbal O, Hoppensteadt D, Fareed J. Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins. Semin Thromb Hemost 1995; 21: 193–200.CrossRef Jeske W, Lormeau JC, Callas D, Iqbal O, Hoppensteadt D, Fareed J. Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins. Semin Thromb Hemost 1995; 21: 193–200.CrossRef
45.
Zurück zum Zitat Gilly G, Trusheim J. Con: The Hepcon HMS should not be used instead of traditional activated clotting time to dose heparin and protamine for cardiac surgery requiring cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2016; 30: 1730–2.CrossRef Gilly G, Trusheim J. Con: The Hepcon HMS should not be used instead of traditional activated clotting time to dose heparin and protamine for cardiac surgery requiring cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2016; 30: 1730–2.CrossRef
46.
Zurück zum Zitat Ichikawa J, Mori T, Kodaka M, Nishiyama K, Ozaki M, Komori M. Changes in heparin dose response slope during cardiac surgery: possible result in inaccuracy in predicting heparin bolus dose requirement to achieve target ACT. Perfusion 2017; 32: 474–80.CrossRef Ichikawa J, Mori T, Kodaka M, Nishiyama K, Ozaki M, Komori M. Changes in heparin dose response slope during cardiac surgery: possible result in inaccuracy in predicting heparin bolus dose requirement to achieve target ACT. Perfusion 2017; 32: 474–80.CrossRef
47.
Zurück zum Zitat Garvin S, FitzGerald DC, Despotis G, Shekar P, Body SC. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg 2010; 111: 849–55.CrossRef Garvin S, FitzGerald DC, Despotis G, Shekar P, Body SC. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg 2010; 111: 849–55.CrossRef
48.
Zurück zum Zitat von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–7. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–7.
Metadaten
Titel
Titrated versus conventional anticoagulation management for thrombin generation in cardiac surgery: a randomized controlled trial
verfasst von
Han Li, MSc, CPC, CPP
Justyna Bartoszko, MD, MSc
Cyril Serrick, MSc, CPC, MCCP
Vivek Rao, MD, PhD
Keyvan Karkouti, MD, MSc
Publikationsdatum
08.07.2022
Verlag
Springer International Publishing
Erschienen in
Canadian Journal of Anesthesia/Journal canadien d'anesthésie / Ausgabe 9/2022
Print ISSN: 0832-610X
Elektronische ISSN: 1496-8975
DOI
https://doi.org/10.1007/s12630-022-02278-1

Weitere Artikel der Ausgabe 9/2022

Canadian Journal of Anesthesia/Journal canadien d'anesthésie 9/2022 Zur Ausgabe

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.